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Abstract
Purpose A proportion of patients with metastatic colo-
rectal cancer (mCRC) are still able to continue with active
therapy after their progression to fluoropyrimidines, oxa-
liplatin, and irinotecan regimens. Studies suggest that
gemcitabine and fluoropyrimidines are synergic antime-
tabolites. The purpose was to evaluate gemcitabine–cape-
citabine (Gem–Cape) in heavily pretreated mCRC and to
thus assess possible predictive factors for progression-free
survival (PFS) and overall survival (OS).
Patients and methods This analysis was performed on
119 evaluable patients pretreated with fluoropyrimidines,
oxaliplatin, irinotecan, and biological agents between June
2001 and July 2011. Patients received gemcitabine
1,000 mg/m2 day 1 and capecitabine 1,000 mg/m2 bid for
7 days every 2 weeks.
Results The general characteristics were ECOG 0–1,
89 %; male, 68 %, and median age 63 years. In total, 61 %
had received two chemotherapy lines, while 39 % had
received three or more. Objective response rates and stable
disease rates at 3 months were 6.72 and 37.81 %, equalling
a clinical benefit of 44.53 %. The median PFS and OS were
2.87 months [95 % confidence interval (CI) 2.53–3.17
months] and 6.53 months (95 % CI 5.33–8.77), respec-
tively. The most frequent toxicities were grades 1–2,
anemia (22 %), thrombocytopenia (10 %), and hand–foot
syndrome (9 %); grade C3, diarrhea (2 %), with no treat-
ment-related discontinuations. No treatment-related deaths
were reported. Statistical significance was obtained by
subgroups, assessing clinical benefits and objective
responses for PFS and OS. Moreover, patients under 65
tended to have a better PFS.
Conclusion These data suggest that Gem–Cape is a tol-
erable and feasible regimen, associated with clinical benefit
in non-selected, heavily pretreated, mCRC patients.
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Introduction
There is a lack of evidence on the use of chemotherapy in
multi-treated, refractory metastatic colorectal cancer
(mCRC) patients; moreover, alternative treatments have
yet to be standardized their true benefit fully evaluated.
The published data of the few phase III studies [1, 2]
that have been performed in this setting showed unsatis-
factory results for overall survival (OS) with a median of
5.8–6.4 months, highlighting the need for further research
and looking toward new active agents or new chemother-
apy combinations.
Gemcitabine is a pyrimidine analogue that has been
turned into difluorodeoxycytidine triphosphate (dFdCTP)
and inhibits deoxyribonucleic acid (DNA) and ribonucleic
acid (RNA) synthesis by four mechanisms: (1) inhibiting
DNA polymerases (a, b, and d); (2) adhering directly to
DNA, thus prohibiting chain elongation; (3) inhibiting
ribonucleotide reductase, resulting in decreased levels of
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essential deoxyribonucleotides for DNA synthesis; (4) and
finally, incorporating itself into RNA, producing alterations
in its processing and mRNA translation [3, 4].
Capecitabine, another antimetabolite, is an inactive
prodrug that undergoes a complex process to reach its
active form. Capecitabine conversion to 5-fluorouracil (5-
FU) is higher in tumor cells than in normal tissues because
of the higher expression of thymidine phosphorylase [5].
The depletion of the reduced nucleotide pool could
increase the incorporation of the 5-FU metabolite fluoro-
uridine monophosphate (FUTP) into RNA and of FdUTP
into DNA, resulting in damaged RNA and DNA synthesis
and function [6] (Fig. 1).
This analysis evaluates the survival, efficacy, and tox-
icity profile of gemcitabine–capecitabine (Gem–Cape) and
intends to identify possible predictive factors in patients
with mCRC treated in a single university hospital.
Patients and methods
Patient selection
Patients aged C18 years with a diagnosis of mCRC con-
firmed by biopsy and with documented evidence of failure
of fluoropyrimidines; oxaliplatin; irinotecan; and biological
agents, such as bevacizumab, cetuximab, or panitumumab,
were treated with Gem–Cape.
All patients had measurable disease by RECIST criteria
1.1 [7], a performance status of the Eastern Cooperative
Oncology Group (ECOG PS) from 0 to 2 [8], adequate
bone marrow reserve (absolute neutrophils C1,500/ll and
platelets C100,000/ll), adequate hepatic function (total
serum bilirubin B3, the institutional upper limit of normal
(ULN), phosphatase alkaline B10 institutional ULN,
and AST B2.5 institutional ULN), and normal renal func-
tion (serum creatinine \1.5 mg/dl or creatinine clear-
ance[60 ml/min).
Patients could have received first and subsequent lines
of chemotherapy within a clinical trial, but this treatment
must have been stopped at least 4 weeks in advance;
radiotherapy or major surgery was allowed if it had been
completed at least 6 weeks before starting Gem–Cape
treatment. All patients signed written informed consent,
and the compassionate use of gemcitabine was approved by
the local ethics committee.
Treatment
The Gem–Cape regimen used throughout the entire period
consisted of gemcitabine 1,000 mg/m2 IV for 30 min on
day 1 and oral capecitabine 1,000 mg/m2/12 h on days 1
through 7, repeated every 2 weeks.
Treatment fulfillment was evaluated by the oncological
nurses’ registry in the case of gemcitabine and by the
patient’s daily dietary notes in the case of capecitabine.
Patients were treated until they reached progressive
disease (PD) on computed tomography scan (CT), unac-
ceptable toxicity, withdrawal of patient consent, patient
refusal, or at the investigator’s discretion.
Toxicity was assessed using the Common Toxicity
Criteria (CTC-NCI) version 3.0 (http://ctep.cancer.gov)
[9], and doses were titrated based on the laboratory values
and tolerance. Treatment was withheld until resolution of
Fig. 1 Interaction and
synergism involving
fluoropyrimidines and
gemcitabine. Yellow triangles
signal the active metabolites of
this synergistic combination
able to produce direct damage to
nucleic acids. The blue pathway
refers to normal integration of
pyrimidines into DNA and
RNA. The purple line represents
fluoropyrimidines metabolism,
just as the green pathway
depicts to gemcitabine
intervention. Crossroad and so
synergism is located at
tymidylate synthase (TS), being
inhibited directly by
fluoropyrimidine metabolite
FdUDP and indirectly by the
inhibition of the enzyme that
catalyzes TS substratum, dUMP
(deoxiuridine monophosphate)
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grade 3 or 4 hematological toxicities or of non-hemato-
logical toxicities grade C2, except for alopecia and nausea.
According to standard clinical practice, gemcitabine and
capecitabine doses were reduced by 20 % if grades 3–4
neutropenia was present. Likewise, capecitabine alone was
reduced by 20 % if grade C2 hand–foot syndrome of
mucositis or grades 3–4 diarrhea was present on day 15 of
any cycle.
Pretreatment assessments
Pretreatment evaluations included complete physical
examination, ECOG PS, weight, complete blood count,
biochemistry profile (hepatic and renal function tests),
carcinoembryonic antigen (CEA), and a baseline thoraco–
abdomino–pelvic CT. Bone scans, magnetic resonance
imaging, and ultrasound endoscopy were carried out only if
clinically indicated. Physical examination, PS, weight,
evaluation of adverse events, and the laboratory studies
listed above, including CEA, were practiced before every
cycle.
Tumor assessment according to the RECIST 1.1 criteria
was carried out every 4 cycles (2 months). In addition,
after PD or withdrawal from the study medication, the
patients were followed monthly until death.
Study end points
Primary end points assessed activity, evaluated as objective
response rates (ORR) and progression-free survival (PFS).
Secondary end points were OS, toxicity profile, and the
possible predictive factors (age, PS, number of metastatic
sites, surgery, previous monoclonal antibodies use, K-ras
status, ORR, and clinical benefit) that might influence PFS
and OS.
Statistical analyses
The retrospective analysis of prospective recorded data
included efficacy analyses of all patients with an intent-to-
treat (ITT) principle. Safety analyses included all patients
who received at least one dose of Gem–Cape.
The complete response (CR) and partial response (PR)
were considered ORR, and clinical benefit was defined as
ORR plus stable disease (SD), as measured by CT.
PFS was defined as the time between the first date of
treatment administration until the first documentation of
progression and last date of follow-up or death. Treatment-
related death was defined as any death occurring within
30 days following the last dose of this regimen. For
patients without disease progression at the time of the final
analysis, the data on PFS were censored at the last
assessment of the tumor status or at the discontinuation of
treatment due to toxicity.
Likewise, OS was defined as the time interval between
the first date of treatment administration and the day of
death from any cause or the last known alive date (patients
who were alive at the time of the analysis were censored
for survival at the time of their last contact).
Descriptive statistics were reported as proportions and
medians, and all analyses were performed with the log-rank
test for one-sided p values, with an alpha value of 0.05.
Meanwhile, the Kaplan–Meier method was used to esti-
mate PFS and OS. The hazard ratio (HR) was calculated by
the Cox regression function as median values and 95 %
confidence intervals (CI).
Table 1 Characteristics of patients with refractory mCRC treated
with Gem–Cape regimen
n = 119 Percent
Age
\65 years old 68 57.1
C65 years old 51 42.9
Sex
Females 37 31.1
Males 82 68.9
ECOG
0–1 59 49.6
2 60 50.4
Primary tumor localization
Colon 51 42.9
Rectum–sigmoid junction 68 34.1
Rectum 23
Primary tumor surgery
None 9 7.6
Curative 51 42.9
Palliative 59 49.6
Tumor burden
1–2 metastatic localizations 62 52.1
[2 metastatic localizations 57 47.9
K-ras status 47 39.5
Wild type 21 44.7
Mutated 26 55.3
Previous use of monoclonal antibodies
No 62 52.1
Yes 57 47.9
Previous chemotherapy sequence
Oxaliplatin–irinotecan 72 60.5
Irinotecan–oxaliplatin 47 39.5
Gem–Cape line of treatment
Third 72 60.5
Fourth 47 39.5
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The univariate and multivariate analyses of subgroups
included the following: age (\65 vs. C65 years), sex (male
vs. female), ECOG PS (0–1 vs. 2), location of the primary
tumor (colon, rectum–sigmoid vs. rectum), primary reason
for surgery (none, curative, or palliative), tumor burden
(1–2 vs. C2 metastatic locations), ORR (CR and PR vs. SD
and PD), clinical benefit (yes vs. no), previous biological
therapy (yes vs. no), K-ras mutational status (wild type,
mutant vs. unknown), previous chemotherapy sequence
(oxaliplatin–irinotecan/irinotecan–oxaliplatin), and Gem–
Cape line of treatment (third vs. further). We used Pear-
son’s Chi square test for qualitative variables and Student’s
t test and ANOVA for quantitative variables. Logistic
regression and Cox proportional hazards models were the
multivariate models applied to identify the effects of the
predictive factors listed above on PFS and OS. Statistical
analyses were performed using the software R version R
2.15.3 under the terms of the Free Software Foundation’s
GNU General Public License in source code form. Each
regression coefficient (in terms of interaction) was esti-
mated according to the maximum likelihood method and
then statistically tested against the null hypothesis.
Results
Patient population
A total of 119 patients (ITT population) were treated
between June 2001 and July 2011 (see baseline charac-
teristics in Table 1).
The proportion of males was 68.9 %; median age was
63 years (range 36–79), and 89 % had an ECOG PS of 0 or
1. The location of the primary tumor was the colon in 43 %,
rectum–sigmoid junction in 34 %, and the rectum in 23 %.
The most common metastatic sites were liver (80 %), lymph
nodes (58 %), lung (53 %), peritoneum (28 %), and bone
(12 %). In first-line therapies, 8.4 % (n = 10) of patients
received fluoropyrimidines in monotherapy; 66 % (n = 79)
received fluoropyrimidine ? irinotecan ± monoclonal
antibodies; and 25 % (n = 30) received fluoropyrimidine
and oxaliplatin ± biological agents. Capecitabine was the
preferred fluoropyrimidine, used in 53 % of first-line and
70 % of second-line therapies. Monoclonal antibodies were
administered in 34 % of first-line (n = 40) and in 24 % of
second-line therapies (n = 29). Gem–Cape was used in
third line in 61 % of the patients, and 39 % of cases received
this therapy in successive lines.
Efficacy
The median exposure of patients to Gem–Cape treatment was
3.23 months (range 0.43–47.2) and 6 cycles (range 1–23).
One case of CR (0.84 %), seven PR (5.88 %), 45 cases
of SD (37.81 %), and 66 cases of PD (55 %) were
observed. The ORR by ITT analysis was 6.72 %. The
patient who reached CR underwent hepatic metastasecto-
my with complete morphological response, and 4 years
after surgery, the patient maintains a recurrence-free
disease.
The median PFS was 2.87 months (95 % CI 2.53–3.17)
and the median OS was 6.53 months (95 % CI 5.33–8.77).
The survival rate was 50 % at 6 months and 25 % at the
first year. Figure 2a–b shows the Kaplan–Meier estimation
for PFS (A) and OS (B).
Univariate analysis showed statistically significant dif-
ferences for PFS in patients who reached ORR (HR 0.147;
95 % CI 0.046–0.476; p = 0.001) or a clinical benefit (HR
0.242; 95 % CI 0.156–0.374; p = 0.0001). Statistical sig-
nificance was observed for the association between OS and
the previous use of monoclonal antibodies in favor of those
who had not received them. Furthermore, both ORR and
clinical benefit were the most significant factors affecting
survival and PFS in univariate analysis. Younger patients
(\65 years) showed a trend toward better survival
(p = 0.056).
A Cox proportional hazard model was used to adjust
survival curves, taking into account other factors that might
influence PFS or OS. In the multivariate analysis, signifi-
cant differences were found in favor of the subgroups with
lower tumor burdens and those who achieved clinical
benefit and response. For clinical benefit, the logistic
regression analysis revealed lower survival rates in those
who had previously used biological agents. Given that
K-ras status determination only started to come on line as
standard practice in 2008, this datum was available for only
a limited number of patients. Despite this, the examination
of the results according to ‘‘Unknown,’’ ‘‘Mutated,’’ and
‘‘Native’’ K-ras status did not yield statistically significant
differences (Fig. 2c).
The previous sequence of cytotoxic agents did not rep-
resent significant differences in survival or clinical benefit
(Table 2).
Toxicity
The toxicity events are listed in Table 3, with 94 %
experiencing the most frequent grade 1–2 events: hand–
foot syndrome (66 %), anemia (23 %), and vomiting
(11 %). Grades 3–4 toxicity occurred in 6 % of the epi-
sodes, most of which were diarrhea. No treatment-related
deaths were documented.
Treatment compliance was 100 %. Delays were neces-
sary in 13 % of cases (15 patients), and dose reduction was
required in 6 % of cases (7 patients).
Clin Transl Oncol (2015) 17:384–392 387
123
Discussion
The use of irinotecan, oxaliplatin, fluoropyrimidines,
and the incorporation of biological agents such as
bevacizumab, cetuximab, and panitumumab, has improved
considerably ORR, PFS, and OS in patients with mCRC [2,
10–12]. Nevertheless, despite all of these drugs, patients
become refractory; their lack of any standardized treatment
Fig. 2 Kaplan–Meier survival curves for OS (a, left panel), PFS (b, right panel) and according to K-ras mutation status (c)
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Fig. 2 continued
Table 2 Multivariate analysis for PFS, OS, and clinical benefit
Progression-free survival (cox regression) Overall survival (cox regression) Clinical benefit (logistic regression)
p HR CI 95 % p HR CI 95 % p HR CI 95 %
INF SUP INF SUP INF SUP
Age\65 0.108 1.404 0.928 2.125 0.252 1.290 0.834 1.996 0.748 0.870 0.371 2.038
KPS\70 0.490 1.152 0.771 1.721 0.498 0.864 0.567 1.318 0.204 0.583 0.253 1.341
Tumor burden 0.424 1.174 0.792 1.739 0.739 0.936 0.634 1.381 0.480 0.743 0.326 1.694
Previous McAb 0.139 0.729 0.480 1.108 0.402 0.835 0.548 1.272 0.001 0.246 0.105 0.575
Previous chemotherapy
Sequence
0.758 1.074 0.683 1.687 0.071 1.529 0.965 2.422 0.589 1.289 0.513 3.240
Line 0.006 1.803 1.187 2.739 0.052 1.506 0.997 2.275 0.835 1.095 0.467 2.569
ORR achieved 0.007 0.181 0.052 0.632 0.086 0.339 0.099 1.166
Clinical benefit 0.000 0.223 0.136 0.367 0.000 0.235 0.138 0.401
Bold values indicate statistical significance (p\ 0.05)
KPS Karnofsky performance status, McAb monoclonal antibody, ORR overall response rate, HR hazard ratio, CI confidence interval, INF inferior, SUP
superior
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alternatives reflects the necessity to continue efforts to
uncover new schedules or drugs that are not only beneficial
in terms of their action, but also in terms of their tolera-
bility and effects on the quality of life.
Currently, very few trials have clearly shown a survival
advantage for any regimen or particular drug in chemore-
fractory patients with mCRC; instead, the main advance
has been the incorporation of antitarget therapies, such as
panitumumab and regorafenib, both of which have been
evaluated in phase III studies [2, 12]. Regorafenib showed
an ORR of 1 %, disease control in 41 %, PFS of
1.9 months, and OS of 6.4 months. In comparison with
placebo, regorafenib produced a benefit of 1.4 months, but
also grade 3 toxicity (hand–foot syndrome, fatigue,
hypertension, diarrhea, and rash) in more than 5 %. With
conventional chemotherapy, nevertheless, advances have
been limited. Thus, Gem–Cape has emerged as an
exploratory treatment due to the synergy of these antime-
tabolites [13].
In vitro studies in CRC have demonstrated the synergy
of gemcitabine with 5-FU [14], and phase I and phase II
trials have evaluated doses, efficacy, and toxicity of this
combination in patients with refractory tumors, especially
in those with pancreatic and colorectal cancers [15]. Thus,
gemcitabine and fluoropyrimidines have been evaluated in
at least eight phase I or phase II studies [13, 15–21],
showing an ORR of 30–38 % in naive patients but of
3.8–10.8 % in refractory cases after the failure of two or
more chemotherapy lines during oxaliplatin and irinotecan
regimens, with PFS of 2.7–4.2 months, and OS of
between 8.9 and 11.3 months. Toxicity in these studies
was manageable [22]. These data suggest that Gem–Cape
is very attractive in patients with refractory mCRC, as
demonstrated in some preclinical and phase I–II trials [13,
15–21]. Still, questions as to appropriate dosages and
schedules have not been fully resolved. In the present
series, most patients used capecitabine in second line;
maintenance of activity and synergy with other drugs,
including gemcitabine, was sought in third and subsequent
lines of treatment. In order to take advantage of this
synergy and consolidated activity of fluoropyrimidines in
mCRC, we used a combination of Gem–Cape after the
disease had progressed to oxaliplatin- and irinotecan-
based regimens.
Table 3 Toxicity of Gem–Cape according to NCI CTC version 3.0
criteria
Toxicity Grades 1–2 Grades 3–4
n % n %
Anemia 26 22.61
Thrombocytopenia 12 10.43
Hand–foot syndrome 10 8.70 1 0.87
Asthenia 10 8.70
Nausea/vomiting 9 7.83 1 0.87
Pseudoflu syndrome 7 6.09
Mucositis 7 6.09
Diarrhea 7 6.09 3 2.61
Neuropathy 3 2.61
Alopecia 3 2.61
Allergic reactions 1 0.87
Table 4 Studies with gemcitabine and fluoropyrimidines in refractory mCRC
Study Chemotherapy Dose mg/m2/d Frequency N RR (%) Disease
control (%)
mPFS mOS Neutrop.
G3/4 (%)
Fillos [17] Gemcitabine 750 Day 1 every 7 days 9 6 26 3.8 34.8 2.7 11.3 45
5-FU 450 Day 1 every 7 days 9 6
Pachon [19] Gemcitabine 800–1,250 Day 1, 15 every 21 18 0 70 3.7 9.9 0
5-FU (IC) 200 Every 21 days
Bitossi [13] Gemcitabine 1,000 Day 1, 8, 15 every 28 37 10.8 61.8 4.2 8.9 8
5-FU (IC) 200 Every 28 days
Madaje Wicz [20] Gemcitabine 900 Day 1 every 7 day 9 6 21 38 NR NR NR 11
5-FU 450 Day 1 every 7 days 9 6
Schilsky [15] Gemcitabine 1,000 Day 1, 8, 15 every 28 21 9.6 14.4 NR NR 7.5
Capecitabine 1,660 21 day every 28
Fernandez [21] Gemcitabine 900 Day 1 cada 14 21 NR NR 4 9 NR
Capecitabine 2,500 7 day every 14
Qiu [18] Gemcitabine 1,000 Day 1, 8 cada 21 12 0 36.4 2.27 5.57 17
Capecitabine 2,000 14 day cada 21
Current study Gemcitabine 1,000 Day 1 cada 14 119 7 45 2.87 6.53 0
Capecitabine 2,000 7 day cada 14
d day, RR response rate, mPFS median progression-free survival, mOS median overall survival, Neutrop neutropenia
390 Clin Transl Oncol (2015) 17:384–392
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No serious toxicity was detected, and all patients com-
pleted treatment, with 13 % requiring cycle delays and 6 %
dose reductions. Our series appeared to exhibit less toxicity
than Bitossi’s report in 2008, who used continuous infusion
of 5-FU with 36.1 % discontinuation or dose reduction rate
that increased to 69.4 % in cases of gemcitabine [13]. The
same combination was chosen for pancreatic cancer, which
was treated with gemcitabine on days 1, 8, and 15 and with
capecitabine for 14 days every 3 weeks, yielding grades
3–4 neutropenia in 22 % of the patients [23]. In this series,
using gemcitabine on day 1 and weekly capecitabine for
every 2-week cycle, the rate of grades 3–4 neutropenia was
0 %. Therefore, Gem–Cape is more manageable and tol-
erable than a continuous infusion of 5-FU associated with
gemcitabine weekly for 3 weeks.
Despite the lower-dose intensity, the ORR achieved was
6.72 %; disease control 44.53 %; PFS 2.87; and OS
6.53 months. It was probably influenced by second line and
no monoclonal treatment in a subgroup of patients. These
data are comparable to those reported in heavily pretreated
mCRC [13, 17, 18]. The ORR and clinical benefit were
relevant because they are seemed to be the best predictive
factors for survival (OS and PFS) in multivariate analysis.
Bitossi et al. [13] published an ORR of 10.8 % in 37
patients, Fillos et al. [17] reported 3.8 % in 26 patients, and
Qiu 0 % in 12 patients [18]. In 2009, Merl et al. [22]
published a review of refractory mCRC patients with a PFS
of 2.7–4.2 months. Thus, based on the historical data, this
regimen appears to provide a clinical advantage over
combinations using a gemcitabine dose intensity of
1,000 mg/m2 and capecitabine dose intensity of 2,000 mg/
m2, 7 days every 2 weeks; this combination has been
shown to have a similar ORR to that of others reported
schemes, as shown in Table 4.
These results support the conclusion that under specific
circumstances, including response to previous treatment
lines; less aggressive tumor behavior; ECOG PS B2; and
good liver, kidney, and bone marrow function, a new
chemotherapy regimen, such as the one used here, might be
useful in heavily pretreated mCRC.
Furthermore, achieving clinical benefit or response had
an impact on survival (OS and PFS) and was an indepen-
dent predictive factor for these survival outcomes, as
demonstrated by univariate and multivariate analyses.
These results lead us to believe that the benefit obtained
with this chemotherapy alternative remains stable. This
series revealed a strong tendency toward higher survival
rates and greater clinical benefit among patients who had
Fig. 3 Number of patients per
year (a) and K-ras mutation
status before and since 2008 (b)
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not received biological agents in previous regimens, sup-
porting the rebound effect paradigm or a subgroup with a
worse prognosis. The first concept was demonstrated after
the suspension of monoclonal antibodies use, as well as the
favorable outcomes achieved when these treatments were
administered and maintained [24].
The major limitations of this study included the uni-
centric origins of the data, many years of data collection,
the retrospective nature of the analysis, and the lack of a
control group. As shown in Fig. 3, despite the long period
of time, patients are distributed among the 10 years and
following clinical guidelines, the state of the K-ras gene is
known in most since 2008.
In summary, Gem–Cape seems to be active, possessing
manageable toxicity and the capacity to accommodate
heavily pretreated patients with mCRC who may not be
eligible to participate in clinical trials. Nevertheless, further
studies will improve our understanding of better chemo-
therapeutic approaches for ‘‘real-life’’ clinical practice.
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